Article: Nicotinamide Riboside Protects Optic Nerve from Degeneration: Preclinical Findings

PrevNext
Preclinical Sensory (Auditory/Optical)

Nicotinamide Riboside Protects Optic Nerve from Degeneration: Preclinical Findings

Synopsis

Nicotinamide riboside (NR), a precursor to NAD+, protects optic nerve axons from damage caused by tumor necrosis factor (TNF). In rats, NR reduced axon loss, improved autophagy markers (increased LC3-II, decreased p62), and increased SIRT1 levels in the optic nerve. The enzyme NRK1, which helps convert NR to NAD+, was found in retinal ganglion cells and optic nerve fibers, and NR treatment boosted its expression. Blocking SIRT1 partially reversed NR’s protective effects, suggesting that NR protects axons by enhancing NAD+ metabolism, SIRT1 activity, and autophagy.

Journal

Molecular Neurobiology

Share

Read more

Clinical

Nicotinamide Riboside and Pterostilbene Increase NAD+ Levels in Patients with Acute Kidney Injury: Clinical Findings

Objectives To evaluate the effects of escalating doses of nicotinamide riboside and pterostilbene (NRPT) on blood NAD+ levels and safety outcomes in patients hospitalized with acute kidney injury ...

Read more
Neurological Health

Fixing Imbalanced NAD Metabolism Reduces Effects of Telomere Dysfunction: Preclinical Findings

Synopsis Short telomeres cause diseases like dyskeratosis congenita (DC), which lack effective treatments. This study found that cells from DC patients and telomerase-deficient mice have low NAD+ ...

Read more